<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651441</url>
  </required_header>
  <id_info>
    <org_study_id>HYK-NSCLC</org_study_id>
    <nct_id>NCT02651441</nct_id>
  </id_info>
  <brief_title>D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)</brief_title>
  <official_title>Randomized, Controlled Study of the Safety and Efficacy of D-CIK Immune Cell Combined With Chemotherapy for Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Hornetcorn Bio-technology Company, LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Hornetcorn Bio-technology Company, LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of chemotherapy combined
      with dendritic activated cytokine-induced killer cell (D-CIK) for non-small cell lung cancer
      (NSCLC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 patients with stage Ⅲb～Ⅳ NSCLC will be randomly divided into group A（receive D-CIK
      treatment and chemotherapy) or group B（just receive chemotherapy),and the randomize ratio
      will be 1:1. Patients in group A will receive 3 cycles of D-CIK treatment (every 1 months)
      and 4 cycles of chemotherapy (every 2 weeks).Patients in group B will receive only 4 cycles
      chemotherapy（every 2 weeks).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>3 years</time_frame>
    <description>The assessment will be performed using The European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC-QLQ-C30).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotypic analysis of T cells</measure>
    <time_frame>1 year</time_frame>
    <description>The number of CD3+ (or CD8+ or CD4+ or CD56+) T cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>According to National Cancer Institute Common Terminology Criteria for Adverse Events（NCI-CTCAE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>D-CIK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines,patients will receive 3 cycles of D-CIK treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.</description>
    <arm_group_label>D-CIK</arm_group_label>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.</description>
    <arm_group_label>D-CIK</arm_group_label>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>cisplatinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>D-CIK</intervention_name>
    <description>8×10^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.</description>
    <arm_group_label>D-CIK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient who have singed the informed consent;

          -  Histologically confirmed with NSCLC at stage Ⅲb～Ⅳ;

          -  Expected survival time is more than 2 month;

          -  Eastern Cooperative Oncology Group (ECOG) performance status was 0-2.

        Exclusion Criteria:

          -  Hemoglobin＜8.0 g/dL,White blood cell ＜3 x 10^9/L;Platelet count ＜75 x 10^9/L; ALT,
             AST, BUN and Cr more than normal limits on 3.0 times;

          -  Known or suspected allergy to the investigational agent or any agent given in
             association with this trial;

          -  Pregnant or lactating patients;

          -  Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or
             TreponemaPallidun (TP) infection;

          -  Patients who are suffering from serious autoimmune disease;

          -  Patients who had used long time or are using immunosuppressant;

          -  Patients who had active infection;

          -  Patients who are suffering from serious organ dysfunction;

          -  Patients who are suffering from other cancer;

          -  Other situations that the researchers considered unsuitable for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi Z Zhang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Tumor Hospital of Guangzhou Medical University immunotherapy center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guang P Wang, Physician</last_name>
    <phone>+86 13810661960</phone>
    <email>WangGP@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Z Wang, Professor</last_name>
      <phone>020-66673666</phone>
      <email>WangZY@QQ.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>D-CIK</keyword>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

